SCHEMBL297992

SCHEMBL297992

Cc1nc2cc(N)ccc2n1C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.60
RAD52 P43351 1/20 0.60
ALDH1A1 P00352 7/20 0.58
LMNA P02545 1/20 0.55
MAPT P10636 5/20 0.54
GFER P55789 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
NPC1 O15118 7/20 0.51
HTT P42858 3/20 0.51
HSD17B10 Q99714 2/20 0.51
POLB P06746 1/20 0.51
HPGD P15428 1/20 0.51
RAB9A P51151 6/20 0.49
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
BRPF1 P55201 1/20 0.46
NSD2 O96028 1/20 0.46
HDAC1 Q13547 1/20 0.46
TP53 P04637 1/20 0.45
GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16633753 0.98 KDM4E (0.63) KDM4ERAD52ALDH1A1LMNAMAPT
SCHEMBL521102 0.85 KDM4E (0.55) KDM4ERAD52ALDH1A1LMNAMAPT
SCHEMBL2734327 0.82 KDM4E (0.52) KDM4ERAD52ALDH1A1LMNAMAPT
SCHEMBL20982514 0.81 KDM4E (0.68) KDM4ERAD52ALDH1A1LMNAMAPT
Hydrochloric Acid SCHEMBL6623126 0.81 KDM4E (0.51) KDM4ERAD52ALDH1A1LMNAMAPT
SCHEMBL2251213 0.80 KDM4E (0.71) KDM4ERAD52ALDH1A1LMNAMAPT
SCHEMBL1104855 0.80 RAB9A (0.59) KDM4EALDH1A1LMNAMAPTNPC1
SCHEMBL6230772 0.79 SMN1; SMN2 (0.58) KDM4ERAD52ALDH1A1LMNAMAPT
SCHEMBL3987179 0.79 KDM4E (0.47) KDM4ERAD52ALDH1A1LMNAMAPT
SCHEMBL209641 0.78 KDM4E (0.46) KDM4ERAD52ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025245484-A1 FOXN1 ACTIVATORS THYMOFOX INC. (US) 2025-11-27 WO disclosed
WO-2023102184-A1 BICYCLIC AMINE COMPOUNDS AS CDK12 INHIBITORS INCYTE CORPORATION (US) 2023-06-08 WO disclosed
WO-2022234271-A1 HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2022-11-10 WO disclosed
CN-109776522-B Substituted heteroaryl compounds, compositions and uses thereof 广东东阳光药业有限公司 2020-12-29 CN disclosed
US-10683297-B2 Substituted heteroaryl compounds and methods of use CALITOR SCIENCES, LLC (US) 2020-06-16 US disclosed
US-20190152977-A1 SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE Northern Industrial Area, (CN) 2019-05-23 US disclosed
EP-3244466-A1 ORGANIC LIGHT-EMITTING DEVICE Samsung Display Co., Ltd. (KR) 2017-11-15 EP disclosed
EP-2125787-B1 DERIVATIVES OF N-(HETEROARYL)-1-HETEROARYL-1H-INDOL-2-CARBOXAMIDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2017-03-01 EP disclosed
US-9242943-B2 1,4 oxazines as BACE1 and/or BACE2 inhibitors SIENA BIOTECH S.P.A. (IT) 2016-01-26 US disclosed
EP-2311825-B1 Pyrimidineamines as angiogenesis modulators NOVARTIS AG (CH) 2015-10-07 EP disclosed
WO-2007010144-A1 N-(HETEROARYL)-1-HETEROARYLALKYL-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF SANOFI-AVENTIS (FR) 2007-01-25 WO disclosed
US-20070015756-A1 Chemical compounds NOVARTIS AG (CH) 2007-01-18 US disclosed
US-20070015756-A1 Chemical compounds NOVARTIS AG (CH) 2007-01-18 US disclosed
US-20070015756-A1 Chemical compounds NOVARTIS AG (CH) 2007-01-18 US disclosed
US-7105530-B2 inhibitors of vascular endothelial growth factor receptor-2 kinase; pazopanib and salts; for proliferative retinopathy; anticancer SMITHKLINE BEECHAM CORPORATION (US) 2006-09-12 US disclosed
CN-1723022-A inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2 STERIX LTD (GB) 2006-01-18 CN disclosed
EP-1556040-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 Sterix Limited (GB) 2005-07-27 EP disclosed
US-20040242578-A1 Pyrimidineamines as angiogenesis modulators NOVARTIS AG (CH) 2004-12-02 US disclosed
US-20040143124-A1 Compound STERIX LIMITED (GB) 2004-07-22 US disclosed
WO-2004037251-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 STERIX LIMITED (GB) 2004-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242578-A1 Pyrimidineamines as angiogenesis modulators TYMS, TYMP, DPYD KDM4E 1408/4885RAD52 616/4885ALDH1A1 1108/4885
US-20070015756-A1 Chemical compounds KDR, FLT4, FLT1 KDM4E 1688/4885RAD52 718/4885ALDH1A1 945/4885
US-20190152977-A1 SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE PRKACA, PRKDC, PRKACB KDM4E 1978/4885RAD52 4086/4885ALDH1A1 4070/4885
US-10683297-B2 Substituted heteroaryl compounds and methods of use PRKACA, PRKDC, PRKACB KDM4E 1978/4885RAD52 4086/4885ALDH1A1 4070/4885
US-20040143124-A1 Compound NR4A1, CBR1, NR2C2 KDM4E 893/4885RAD52 762/4885ALDH1A1 553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.